In a thinly-veiled swipe at Donald Trump, the French President says he prefers 'respect to bullies' and the 'rule of law to brutality' ...

Sanofi SAN-0.16%decrease; red down pointing triangle said two bleeding disorder treatments for both chronic and acute conditions have been approved in China, expanding its hematology offerings in the ...

For decades, hospitals have given babies a vitamin K injection to protect against bleeding. Now, the shot appears to be ...

Investing.com -- Sanofi has received approval for two bleeding disorder treatments in China, expanding its hematology portfolio in the country. The French pharmaceutical company announced Thursday ...

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...

Sanofi said two bleeding disorder treatments for both chronic and acute conditions have been approved in China, expanding its hematology offerings in the country. The French pharmaceutical company ...

Results from the largest-ever clinical trial of its kind found administering a synthetic protein can reduce bleeding and improve outcomes for certain patients at the highest risk of continued bleeding ...

About The Study: Cryopreserved platelets did not meet the predefined threshold for noninferiority in hemostatic effectiveness at 24 hours after intensive care unit admission. Additional predefined end ...

Two bleeding disorder treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China. Broadcom Reports Earnings After the Close Today. Analysts Expect Strong ...

Three years after introducing Hemgenix, the first gene therapy for hemophilia B, CSL Behring has released long-term data proving the treatment’s benefits remain durable after five years. The five-year ...